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Bariatric surgery is currently the most effective therapy to induce weight loss in morbidly obese patients.Objective. This controlled,
clinical trial with a two-year intervention was aimed at comparing the efficacy of two nonsurgical approaches versus bariatric
surgery, on body weight changes and metabolic parameters in morbidly obese patients.Methods. Patients were randomized to an
Intensive Lifestyle Intervention (ILI) (𝑛 = 60) or Conventional ObesityTherapy (COT) (𝑛 = 46).The ILI group received behavioral
therapy and nutritional counseling.The COT group received standard medical treatment. They were compared with a third group,
Surgical Obesity Group (SOG) (𝑛 = 37). Results. Patients who received ILI had a greater percentage of weight loss than patients
receiving COT (−11.3% versus −1.6%; 𝑝 < 0.0044). Interestingly 31.4% of patients included in the ILI group were no longermorbidly
obese after just six months of intervention, increasing to 44.4% after 24 months of intervention.The percentage weight loss in SOG
was −29.6% after that same period of time. Conclusions. ILI was associated with significant weight loss when compared to COT, in
a group of patients with obesity. An ILI approach could be an alternative therapy to patients with obesity, who are not candidates
to undergo bariatric surgery. This trial is registered with EudraCT 2009-013737-24.
1. Introduction
Obesity has become an epidemic of global proportions.
Morbid obesity (MO) [body-mass index (BMI) > 40Kg/m2]
is considered the most serious stage of the disease, with a
population prevalence of 6–8% in the US [1] and 1-2% in
Spain [2].Therefore, many people are living with a higher risk
of dying from complications of their obese status, or living
with a disability [3] and/or a psychosocial stigma [4, 5] that
prevents them from enjoying a satisfying life. The general
recommendation to morbidly obese patients, to lose 10% of
their initial bodyweight [6, 7], is well known to have a positive
impact reducing their cardiovascular risk.
Nowadays we can offer two therapeutic approaches to
our patients with MO: the Conventional Obesity Therapy
(COT) currently provided in our endocrine/obesity clinics,
or bariatric surgery.Unfortunately, it is becoming evident that
COT has very limited effect, as the Swedish Obesity Study
[8] and other studies have shown [9–11]. Bariatric surgery,
however, is currently the most effective treatment that we
can offer to the large majority of our patients withMO [8, 12–
15].
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The Socialized Health System in Spain provides weight
loss surgery to less than 6,000 patients with MO every year
[16]. The bariatric surgery waiting list in public hospitals
averages more than two years in Spain and other European
Union countries, and it is estimated that, with the current
strategy, only one in every 200 patients with MO will
undergo bariatric surgery [17]. There is indeed a significant
mismatch, between patients who potentially could benefit
from a bariatric procedure and the actual number of subjects
who undergo surgery. The associated costs of taking care of
these morbidly obese patients, many of them with important
comorbidities, are therefore expected to increase in the near
future. Patients with MO, in many instances, are visited
by different specialists due to their multiple comorbidities,
while no one addresses comprehensively their main medical
problem, which is their obesity.
This problem is acquiring dramatic proportions and
underlines the need to implement and develop efficacious
obesity treatments (alternative to bariatric surgery), so that
we can effectively treat our nonsurgical candidates, morbidly
obese patients. There are already some studies showing
the beneficial effects of behavioral +/− pharmacotherapy
interventions [18–23]. However, few of these studies have
included patients with MO in the context of a prospective,
randomized clinical trial.
We designed a 24-month controlled, clinical trial with
a six-month follow-up, to compare the health impact of
an Intensive Lifestyle Intervention (ILI) on patients with
MO, compared to Conventional Obesity Therapy (COT)
and bariatric surgery. We aimed to test whether an ILI was
effective in helping patients with MO to significantly lose
weight andmaintain this weight loss sixmonths after the trial.
2. Materials and Methods
2.1. Participants. This report expands our previous trial pub-
lication from one year to two years plus a six-month follow-
up period [24]. Individuals withMO (BMI > 40Kg/m2) were
selected from our obesity clinic in Son Espases University
Hospital in Mallorca (Spain). These patients were not paid to
participate, nor did they pay any medical costs. All patients
providedwritten informed consent to participate in the study.
Additional written informed consent was obtained prior to
any surgical procedure.The studywas reviewed and approved
by the Balearic Islands Human Ethics Committee (reference
number IB 451/05) in accordance with the guidelines of the
Helsinki Declaration.
Inclusion criteria were (1) age between 18 and 65 years,
(2) men or women of any ethnic group with a BMI >
40Kg/m2, (3) arterial pressure < 160/100mmHg, (4) a fasting
triglycerides concentration < 600mg/dL, and a glycosylated
hemoglobin (HbA1c) level < 11%. The exclusion criteria
included drug or alcohol abuse, pregnancy, enrollment in
other obesity interventions, previous bariatric surgery, men-
tal disorders (depression and anxiety which were considered
manageable by the principal investigator were not criteria
for exclusion) and/or physical impairment, or any other
criteria which could interfere with the ability to comply with
treatment as previously detailed [24].
2.2. Intensive Lifestyle Intervention (ILI) Group. Patients
assigned to receive ILI behavioral modification attended
weekly group meetings from week one through week 12.
Subsequently, sessionswere conducted biweekly fromweek 13
to week 52. Meetings lasted for 90 minutes, included 10 to 12
subjects, and were led by a registered nurse with a master’s in
nutrition.The group sessions were focused on the qualitative
aspects of dietary habits, as the distribution of energy intake,
frequency of consumption, and food choices. We provided
information on the benefits of the Mediterranean diet and
encouraged our patients to comply with this diet. There were
no restrictions in caloric intake. Subjects were instructed to
complete weekly homework assignments during a 72-hour
period to develop perspectives on food preferences and meal
patterns.
A sports medicine specialist prescribed daily exercise (led
by a physiotherapist), physical self-checks, and stretching
without resistance, in sets of two minutes every four to six
hours coordinated with breath control, before performing
aerobic exercise.
Patients, who were eligible, could receive treatment with
weight loss medicines, such as Orlistat (Xenical, Roche,
USA), or antidepressants at the physician’s discretion. Forty
per cent of the patients included in this group received
treatment with sibutramine (Meridia, Abbot Laboratories,
USA) for a period of only one to two months until it was
withdrawn from the market in January of 2010.
2.3. Conventional Obesity Therapy (COT) Group. Patients in
this group received standard available nutritional education,
medical treatment, and follow-up available for MO patients
as per the Spanish Endocrine Society protocol. Patients had
regular clinic visits with an endocrinologist, dietitian, and
nurse every three to six months throughout the duration of
the study. Medical therapies, including the use of pharmaco-
logical agents, were determined by their endocrinologist on
an individual basis. Only 15% of patients received weight loss
medications.
2.4. Surgical Obesity Group (SOG). The SOG was constituted
by those patients, already included in the Bariatric Surgery
Program at our hospital and it was intended to be an
additional control group.We included 37 consecutive patients
who were willing to participate. Patients underwent a laparo-
scopic biliopancreatic diversion (BPD) which is routinely
performed at our Institution, following guidelines of the
Spanish Obesity Society (SEEDO) [25].
2.5. Objectives. The main objective of the TRAMOMTANA
study (Tratamiento Multidisciplinar de la Obesidad Mo´rbida:
Medicamentos, Terapia de comportamiento, Apoyo Nutri-
cional y Actividad Fı´sica, or Multidisciplinary Treatment of
MorbidObesity: Drugs, BehavioralTherapy, Nutritional Sup-
port and Physical Activity) was to evaluate, in patients
with morbid obesity, the impact of an intensive, multidis-
ciplinary, nonsurgical weight loss program, including nutri-
tional assessment, promotion of physical activity, medica-
tions, and support in the process of change in lifestyle.
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Figure 1: Consort flow chart follow-up 24 + 6.
2.6. Primary and Secondary Outcomes. The primary out-
comes of body weight (Kg) and BMI (Kg/m2) were measured
at all study visits. Height and weight were measured with
the subjects barefooted and lightly dressed, with a Tanita’s
WB-3000 digital beam scale with a mechanical height rod,
allowing height to be measured the same time as weight in
the first visit. Height was taken at head level to the nearest
centimeter, with the subject standing barefooted, with feet
together and following the plane of Frankfurt. BMI was
calculated as weight in kilograms divided by the square
of height in meters. Circumferences were measured to the
nearest cm using a flexible tape with the subject standing.
Weight was measured weekly during the first three months,
biweekly for 21 months in the ILI, and every three months in
the COT and bariatric surgery groups, during routine visits,
with both surgeon and endocrinologist.
Secondary outcome measures included percent changes
in fasting plasma glucose (FPG), glycosylated hemoglobin
(HbA1c), and blood pressure (BP) and of fasting lipids
obtained at baseline and every three months after initi-
ation of the intervention. A 40mL fasting blood sample
was obtained from an antecubital vein. Samples were pre-
pared using low speed centrifugation at 4,000 g for ten
minutes and stored in our hospital Registered Biobank.
Major obesity-related comorbidities, including hyperten-
sion, hypercholesterolemia, and hypertriglyceridemia, were
assessed for changes after intervention by evaluation of blood
tests. Seated BP and pulse weremeasured on each occasion in
duplicate, using an automated device after a five min rest.
2.7. Randomization-Sequence Generation. Randomization to
either ILI or COT was computer-derived, after all eligibility
criteria were confirmed, and the study was not blinded
(Figure 1).
2.8. Sample Size and Statistical Analysis. The sample size was
calculated with enough power to be able to detect clinically
significant effects in percent changes of weight from baseline
and one year after intervention (𝑝 > 0.80). Given the
longitudinal character of the study and the need for changes
in food patterns, we expected that 50% of the patients in the
intervention group (ILI) would not finish the trial, because of
losses to follow-up, so we conservatively increased the sample
size to 60 subjects randomized to the intervention arm of the
study (ILI group), that is, 50% of the sample size. The first
control group (COT group) would hold a proportion of 25%
of the sample size; and finally the SOG group would hold
the remaining proportion of 25%. Given a type one error
of 5%, with 80% power, and taking into account a baseline
BMI of 45Kg/m2, with a standard deviation of 4-5 Kg/m2,
and considering a clinically relevant reduction of BMI to be
at least four units in kg/m2, equivalent to a 10%, we required
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a minimum sample size of 60 ILI, 30 COT, and 30 SOG
patients.
We compared normalized continuous variables between
groups at baseline using analysis of variance and Fisher’s
test. We compared categorical variables at baseline using chi-
square test. Changes at the 24th month for continuous vari-
ables were expressed as overall percentage unitary variation
(mean ± SD; percentage unitary change between initial value
and end value; paired samples, i.e., percentage change per unit
patient) in comparison with the same patients at baseline.
It was tested by a planned sequential procedure in which
an analysis of variance was performed first and Bonferroni
pairwise analyses were performed to compare treatments in
case of global significance.
Continuous variables are reported as mean ± SD and
categorical variables as number and percentage. A𝑝 value less
than 0.05 was considered statistically significant. Data were
analyzed using R-project version 2.12.0.
3. Results
The baseline demographic and clinical characteristics of the
three study groups are shown in Table 1. The mean age of
participants was 46.5±10.7 years, 31.4%weremale, and 98.3%
wereCaucasian.Therewere no racial/ethnic differences, body
weight, or other parameters at baseline among the three
groups. Just the BMI of the SOG group was higher, due to
a weight bias selection in the patient included in the surgical
waiting list.
3.1. Weight Loss. After two years of intervention, patients
who received ILI had a higher percentage of weight loss than
patients in the COT group, −11.3 ± 8.7 (ILI), −1.6 ± 7 (COT)
% weight Loss (Table 2).
Figure 2 shows that % weight loss (primary endpoint),
in the COT, ILI, and SOG groups, respectively, was 0.6%,
−10.5%, and −30.8% for year one and −1.6%, −11.3%, and
−29.6% for year two; and finally at the end of the study the
% weight loss was −3.3%, −9.6%, and −30.3%.
Figure 2 also depicts BMI (secondary endpoint), in the
COT, ILI, and SOG groups: 47.2 ± 5.3, 45.8 ± 5.5, and 49.5 ±
5.7, respectively, at baseline; 46.37 ± 4.83, 40.15 ± 5.33, and
33.83 ± 5.82, at the end of year one; 46.2 ± 5.4, 40.6 ± 6.9, and
34.4 ± 6.1 at the end of year two; and finally, after the follow-
up period, the BMI was 46.4 ± 5.1, 39.6 ± 5.1, and 34.1 ± 6.4,
respectively (Table 3).
As expected, the weight loss achieved with ILI was vari-
able (Figure 3(a)) and we identified four levels of weight loss
response, after two years of intervention. 21.6% of patients in
the ILI group were super obese (BMI > 50Kg/m2) and 78.3%
had a BMI >40–<50 kg/m2. Of interest, 61% of patients who
completed the two years of ILI therapy had accomplished a
reduction of BMI to non-MO levels, and therefore they were
not candidates for bariatric surgery anymore. Also 11.1%of ILI
patients achieved a BMI < 30 kg/m2 that would classify them
as only overweight patients. The percentage of super obese
patients (BMI> 50 kg/m2) who completed the two-year study
was 23.1%. However, 66.7% of these patients had their obesity
category from super obese to MO (Figure 3(b)).
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Figure 2: Percent weight loss from baseline, one year, two years.
21.7% of the subjects in the COT group discontinued the
study at year one, and this number increased to 36.9% at
the end of year two (Table 2). 41.7% in the ILI group did
not complete the one-year study, whereas 70% of participants
had dropped the study after two years (Table 2).This number
included anyone who attended the first treatment visit but
did not return. Seven subjects (18.9%) in the surgical group
were lost to follow-up within the first year and 37.8% did
not show up for their 24-month follow-up visit. The patients
who abandoned the study did so because of changes in
social and employment status or the development of medical
complications unrelated to the intervention that prevented
them from complying with the study protocol.
3.2. Impact on Biochemical Markers of Type 2 Diabetes. Mean
FPG in mg/dL decreased after one year of ILI, from 135.6 ±
45.2 to 112.3±37.3mg/dL, compared to a change from 119.3±
47.3 to 124 ± 63.2mg/dL in the COT group as previously
shown [25]. Data at two years showed that the mean FPG
improved by 12.7% ± 24.2 in the ILI group while the COT
group increased 4.3% ± 30.8%. However, these differences
were not statistically significant (𝑝 = 0.09). The SOG’s mean
FPG decreased from 106.8 ± 20.5 to 92.1 ± 14.5mg/dL.
We also compared HbA1c changes in the subgroup of
Type 2 diabetic patients included in the three arms of the
study. While there were no statistically significant differences
among the three groups, HbA1c slightly improved in all COT
patients (−3.1% ± 20.5%) and in the SOG (−8.4% ± 9.8%),
while patients in ILI did not change (0.4% ± 9%) (Table 2).
3.3. Impact on Other Biomarkers. In lipid levels, HDL-C
levels showed an improvement in all three groups (also both
in men and in women) after two years of participation in
International Journal of Endocrinology 5
Table 1: Demographic and clinical characteristics of patients∗.
Characteristic ILI (𝑁 = 60) totalpopulation
COT (𝑁 = 46) total
population
SOG (𝑁 = 37) total
population 𝑝 value
†
Age, yr 47.8 ± 11.5 46.9 ± 10.3 44.1 ± 9.8 0.2533
Male/female sex, number (% male) 17/43 (28.3) 17/29 (37.0) 11/26 (29.7) 0.6164
Weight, Kg 122.2 ± 20.1 126 ± 17.9 132.8 ± 24.4 0.0526
Height, cm 1.63 ± 0.1 1.64 ± 0.1 1.64 ± 0.1 0.8161
Body-mass index‡ 45.8 ± 5 46.8 ± 4.6 49.2 ± 5.9 0.0068
Systolic blood pressure 131.9 ± 18.7 136.1 ± 14 132.6 ± 14.4 0.3933
Diastolic blood pressure 86.8 ± 10 86.6 ± 10 82.8 ± 8.9 0.1129
Heart rate 82.9 ± 11.7 89 ± 10.6 81 ± 7.9 0.0014
Cholesterol (mg/dL)
Total 202.8 ± 37.2 194.4 ± 31.8 178.8 ± 38 0.0067
High-density lipoprotein 49.4 ± 10.4 44.1 ± 9.1 40.2 ± 6.2 <0.0001
Low-density lipoprotein 121.8 ± 31.8 119.2 ± 23 118 ± 28.9 0.7915
Triglycerides (mg/dL) 162 ± 62.4 151.4 ± 66.7 136.5 ± 63.9 0.1647
Fasting glucose (mg/dL) 122.1 ± 40.1 116.4 ± 40.6 110.4 ± 26.9 0.3242
Glycated hemoglobin, % 6.7 ± 1.7 (𝑁 = 15) 7.8 ± 1.7 (𝑁 = 11) 6.4 ± 0.8 (𝑁 = 9) 0.2291
Diabetes, number (%) 15 (25) 11 (23.9) 9 (24.3) 0.9905
Study level
Basic, number (%) 42 (70.0) 33 (71.7) 34 (91.89) 0.0333
Medium, number (%) 12 (20.0) 9 (19.6) 3 (8.1) 0.2601
High, number (%) 6 (10.0) 4 (8.7) 0 (0.0) 0.148
Marital status
Single, number (%) 11 (18.3) 12 (26.1) 11 (29.7) 0.3985
Married, number (%) 37 (61.7) 26 (56.5) 15 (40.5) 0.1208
Widowed, number (%) 4 (6.7) 2 (4.3) 2 (5.4) 0.8744
Separated & divorced, number (%) 8 (13.33) 6 (13.03) 9 (24.32) 0.2847
Birth country
Spain, number (%) 58 (96.7) 42 (91.3) 34 (91.9) 0.4611
Latin American, number (%) 1 (1.7) 3 (6.5) 2 (5.4) 0.4256
Rest of Europe, number (%) 1 (1.7) 1 (2.2) 1 (2.7) 0.9411
Tobacco use
Current smoker, number (%) 9 (15.0) 10 (21.7) 7 (18.9) 0.6659
0–20, number (%) 1 (11.1) 7 (70.0) 5 (71.4) 0.0307
>20, number (%) 8 (88.9) 3 (30.0) 2 (28.6) 0.3993
Past or never, number (%) 51 (85.0) 36 (78.3) 30 (81.1) 0.6659
Race
Caucasian, number (%) 59 (98.3) 44 (95.6) 35 (94.6) 0.5788
Other races, number (%) 1 (1.7) 2 (4.3) 2 (5.4) 0.5788
Diabetes, number (%) 15 (25.0) 11 (23.9) 9 (24.3) 0.9905
Fasting glucose (mg/dL) 122.1 ± 40.1 116.4 ± 40.6 110.4 ± 26.9 0.3242
Glycated hemoglobin, % 6.7 ± 1.7 (𝑁 = 15) 7.8 ± 1.7 (𝑁 = 11) 6.4 ± 0.8 (𝑁 = 9) 0.2291
∗Plus-minus values are means ± SD.
†
𝑝 values are for comparisons within the three groups.
‡The body-mass index is the weight in kilograms divided by the square of the height in meters.
ILI: Intensive Lifestyle Intervention, COT: Conventional Obesity Therapy, and SOG: Surgical Obesity Group.
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Figure 3: Changes in BMI up to year two, by morbid obesity thresholds.
the trial, except for women included in the COT group.
Regarding TG levels, both ILI and SOG participants showed
reductions in their % change plasma levels, 8.7 ± 27.2 and
15.7 ± 32.7mg/dL, respectively, compared to no changes in
those receiving COT (−0.1 ± 21.6mg/dL). However, these
differences were not statistically significant among the three
groups at two years (Table 2).
Mean LDL-C level did not show statistically significant
improvement in the ILI group compared to the COT group
after two years, whereas patients from the SOG showed a
significant improvement in this parameter (𝑝 < 0.0001). The
mean level of LDL-C in the SOG showed an improvement
(27.7% ± 21.4%), which was statistically significant com-
pared to the other two groups; ILI 5.2% ± 22.2% and COT
−1.5% ± 16.4% (𝑝 < 0.0001).
Finally, there was a significant reduction of serum triglyc-
eride levels in the ILI group of −8.7 ± 27.2% after two years
of intervention compared with a small change in triglyceride
levels (−0.1 ± 21.6%) in the COT group. The surgical group
also showed an improvement in their triglyceride levels
(−15.7 ± 32.7%) (Table 2).
3.4. Blood Pressure and Heart Rate. Systolic and diastolic
blood pressure levels were neither significantly different
among the three groups, nor significantly different after one
year or two years of intervention. Pulse showed a significant
improvement in the ILI and COT compared to SOG, after
two years of intervention; however baseline pulse values
were originally higher at baseline in these two medically
treated groups.Therewere no statically significant differences
in pulse values among the three groups after two years of
intervention (Table 2).
3.5. Surgical Outcomes and Complications. Thirty-seven
patients underwent bariatric operations (biliopancreatic
diversion).Themedian length of hospital stay was eight days.
The overall major complication rate was 2%. Among the
most frequent ones were infection 3%, bleeding 2%, gas-
trointestinal fistula 2%, and pulmonary thromboembolism
0.2%. Minor complication rate was 10%. These included
gastrointestinal (diarrhea 15%), nutritional deficiencies (iron
25%, Vitamin B12 30%, calcium/Vitamin D 50%, and hypoal-
buminemia 5%), incisional hernias (3%), pneumonia (2%),
and wound infections (5%).
3.6. Six-Month Extension after Trial Completion. We asked
all patients who had completed the two-year intervention
to come back for a follow-up visit six months after the
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completion of the study. Fourteen subjects in the ILI group
attended this 30-month follow-up visit, whereas 19 patients
in COT and 23 in SOG came to this visit.
At this follow-up evaluation, six months after the end of
the intervention period, patients who received ILI continued
to have a higher percentage of weight loss as compared
to patients in COT. Namely, subjects in ILI maintained a
weight loss of −9.6% ± 7.8%Kg compared to the weight loss
of −3.3% ± 7.3% in the COT group (𝑝 = 0.23) (Table 3). The
surgical group maintained a weight loss of 30.3% ± 12.6%.
The mean fasting plasma glucose continued to be better
in the ILI group (−16.4% ± 22.4%) compared to the COT
group (−1% ± 28.1%). The SOG group showed a fasting
glucose improvement of 11% ± 18.4%, but these differences
were not statistically significant (𝑝 = 0.1517). The HbA1c
was slightly lower in the type 2 diabetic patients included
in SOG compared to the ILI and COT patients, but again
there were no statistically significant differences among the
three groups (Table 3) (𝑝 = 0.1). LDL-C was improved
in the SOG group, which was statistically significant when
compared to the other two medical groups (𝑝 < 0.05)
(Table 3). Neither systolic nor diastolic blood pressure nor
heart rate changed significantly among the three groups after
this 6-month follow-up period.
4. Discussion
Previous studies have shown the benefits of ILI compared to
COT in obese patients [18–23]. The results of this two-year
clinical trial TRAMOMTANA extend these observations to
patients with MO and compare them to patients undergoing
bariatric surgery. The morbidly obese patient population
is a subgroup of obese population whose relative size is
increasing the fastest and consumes the largest proportion of
the Health National Budget (due to its comorbidities), and
approximately less than 2% of MO patients will eventually
undergo bariatric surgery.
Current guidelines indicate that obese patients should
visit a specialist in order to lose weight and prevent obesity-
related conditions [26]. The reality is that a myriad of
patients with MO are followed up on a regular basis (every
four to six months) in our obesity clinics worldwide, with
losing significant weight. Unfortunately the current medical
therapeutic approach to this chronic condition is not effective
in helping these patients to lose weight in the long term, at
least for more than two years. Therefore, it seems imperative
for the sake of our patients and our Health System that
we design effective obesity therapeutic approaches in the
hospital and/or primary care settings, more efficacious than
our current obesity treatments and potentially an alternative
therapy to patients not interested in/suitable for undergoing
bariatric surgery.
Recent publications have shown the efficacy of ILI on
obese and type 2 diabetic patients with MO [9, 11, 20]. In the
Look AHEAD study at year one, participants in the ILI had
lost 8.6 kg of initial body weight, compared to 0.7 kg only in
the COT group. At year 4, participants in the ILI maintained
a weight loss of 4.9 kg in comparison with only 1.3 kg loss, in
COT. In a two-year randomized clinical trial, Ryan et al. [11]
showed that patientswithMOrandomized to ILI in a primary
care setting lost a significant amount of weight, compared to
those receiving COT (21% of patients lost 10% or more of the
initial weight). In agreement with the data presented in this
manuscript, the authors reported aweight loss of 5%or higher
in 31% of patients and a 10% weight loss in 21% of cases, with
a significant improvement in several metabolic parameters.
They also reported that retention (51% in the ILI group) and
weight loss maintenance were two key points which had to be
improved in subsequent studies.
There is general agreement that one of the major chal-
lenges of all weight loss programs is to maintain any weight
loss achieved, over the medium and long term period [25].
It is important that patients undertake lifestyle changes
durable enough, to allow a significant improvement in their
comorbidities, quality of life [27, 28], and body composition
[29].
In a one-year nonrandomized controlled trial [30], John-
son et al. showed that an ILI intervention was associated with
more favorable dietary changes than gastric bypass surgery
in MO patients, as measured by intake of vegetables, whole
grains, dietary fiber, and saturated fat. Others suggest that
current weight loss programs usually achieve a reduction of
7 to 10% of the initial body weight [31, 32] after six to nine
months of intervention, and the combination of diet, physical
activity, and behavioral changes can obtain even better results
if antiobesity drugs are added [33].
TRAMOMTANA is, to our knowledge, the first ran-
domized trial comparing two medical treatments (ILI versus
COT) to induce weight loss in patients with MO, with a
two-year duration. Results presented in this paper indicate
that MO patients included in an ILI obtained an average
weight loss (10%) significantly better compared to the group
of patients receiving COT (1-2%). Patients who followed our
supervised ILI program were more prone to incorporate
healthy lifestyles and exercise in their daily routine. This
study also expands the findings of previous reports, showing
the benefits of lifestyle modifications, by inducing clinically
significant weight loss in nonmorbid obese patients [34].
Limitations of our study include the lack of random-
ization to the surgical arm; patients were only randomized
to the two medical treatments. We could not randomize
patients to bariatric surgery because our surgeons had to
follow the waiting list of patients with MO in our hospital,
already accepted for a bariatric procedure, and also due to
ethical committee concerns. The limited sample size of this
study, however, reached significance inmostmajor andminor
aims, and the fact that it was open label might limit the
strength of the recommendations. As expected, the dropout
rate was significant, however, in agreement with previous
clinical trials involving patients with MO [11]. It is important
to emphasize that during the recruitment process patients
were informed of the possibility of receiving sibutramine
therapy, if they were candidates.The fact that this medication
was removed from the market two months after patients
had started therapy and they had to stop treatment was a
major contributing factor to our significant dropout rate. Our
study was not powered for safety or to detect differences in
endpoints such as mortality or cardiovascular events. Despite
10 International Journal of Endocrinology
these limitations, TRAMOMTANA strongly supports that
ILI represents a potentially effective weight loss strategy
for management of patients with MO. This effect should
significantly improve, if weight loss medications are added to
ILI. It is important to point out that ILI patients significantly
lost weight after receiving advice on a more healthy lifestyle
and Mediterranean diet, while there were no restrictions in
caloric intake and they did not use dietary supplements or
low caloric diets.
We consider that our findings are relevant, given the
evident mismatch between the number of patients with MO
and the actual number of MO patients who may undergo
a bariatric procedure. Despite the much larger weight loss
observed in the surgical group, an average body weight loss of
10% obtained with ILI represents a reduction of four units of
BMI, which can produce an important health benefit for our
patients, a 40% reduction in our bariatric surgery waiting list,
and important health costs savings.
Finally, our trial also underlines an important issue
which is currently receiving little notoriety. It is the fact
that the current therapeutic approach to treat obesity in
general and MO patients in particular, in our clinics, is
not efficacious and perhaps not cost-effective. Our results
provide strong support for the recommendation that ILI can
be used as therapy of MO in the obesity clinic and the
incorporation of ILI therapy in obesity therapy programs
should be seriously considered. The addition of weight loss
medications should be seriously considered. ILI programs
can help to better identify which patients are suitable for
benefitting from medical therapy, without the need of being
included in the bariatric surgery waiting list. Programs like
TRAMOMTANA should be considered in an effort to early
identify patients, who could benefit from these interventions,
so we can maximize resources and refer to bariatric surgery
only the patients who have previously failed a lifestyle
program, instead of patients who have just failed to comply
with the limited advice received in biannual medical visits.
Furthermore many insurance companies require, following
a medically supervised weight loss program, before giving
approval to obese patients, undergoing a bariatric proce-
dure.
Likely, the addition to ILI programs of the recently
approved new weight loss medications should make these
ILI interventions even more effective. Until we can help our
patients with MO to lose weight and to keep it off with a
medical weight loss program, bariatric surgery will continue
to be the most efficacious way to treat only a minority of our
patients with MO.
To conclude, the TRAMOMTANA two-year trial pro-
vides strong evidence to support the recommendation of
ILI interventions to induce significant weight loss for the
treatment of morbidly obese patients. ILI (with or without
combination with antiobesity drugs) could be their last
chance to regain control over their weight (and their health),
especially if bariatric surgery is not a feasible option.
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